A Single Arm Phase II Study of Pharmacologic Dose Estrogen in Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapies
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival
6 months
No
Mary Daly, M.D.
Principal Investigator
Fox Chase Cancer Center
United States: Institutional Review Board
FER-BR-030
NCT00661531
April 2008
May 2011
Name | Location |
---|---|
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
Cooper Cancer Institute | Camden, New Jersey 08103 |
Georgetown University Medical Center | Washington, District of Columbia 20007 |